File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Monitoring of leukocyte cytomegalovirus DNA in bone marrow transplant recipients by nested PCR

TitleMonitoring of leukocyte cytomegalovirus DNA in bone marrow transplant recipients by nested PCR
Authors
Issue Date1995
PublisherAmerican Society for Microbiology.
Citation
Journal Of Clinical Microbiology, 1995, v. 33 n. 10, p. 2530-2534 How to Cite?
AbstractA nested PCR assay for the detection of human cytomegalovirus (CMV) DNA was evaluated by weekly monitoring of blood samples taken from 101 bone marrow transplant (BMT) recipients. When peripheral blood leukocytes were used as the source of CMV DNA, even a modified assay with stringent temperature-cycling conditions was as sensitive as the standard assay. The sensitivity, specificity, and positive predictive value of two consecutively positive leukocytic PCR results with this modified assay in predicting CMV disease of 101 patients submitting 1,441 peripheral blood leukocyte samples were found to be 92.1, 63.5, and 60.3%, respectively. The positive predictive value of patients' seropositivity for CMV was 40%, while that of viremia was 72%. However, viremia followed CMV disease by a median of 1.5 days, while the first leukocytic positive PCR assay preceded disease by a median of 14 days. By use of the criteria of two consecutively positive PCR results instead of recipient CMV seropositivity for starting preemptive ganciclovir treatment, 38 of the 43 recipients with isolated single positive or negative assays (groups I and II) would be spared unnecessary ganciclovir treatment. Moreover, two other findings support the use of antiviral prophylaxis before engraftment in high-risk cases and subsequent preemptive treatment of patients with two consecutively positive PER assays. First, for 7.9% of 76 patients with positive assays (groups II and III), the first positive PCR assay occurred before engraftment, which implied the presence of viral DNA in the blood (DNAemia) soon after transplantation. Second, isolated single positive assays which were clustered around the second to sixth weeks after transplantation were found for 18 patients (group II) and could represent abortive episodes of CMV infection.
Persistent Identifierhttp://hdl.handle.net/10722/49054
ISSN
2015 Impact Factor: 3.631
2015 SCImago Journal Rankings: 2.151
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYuen, KYen_HK
dc.contributor.authorLo, SKFen_HK
dc.contributor.authorChiu, EKWen_HK
dc.contributor.authorWong, SSYen_HK
dc.contributor.authorLau, YLen_HK
dc.contributor.authorLiang, Ren_HK
dc.contributor.authorChan, TKen_HK
dc.contributor.authorNg, MHen_HK
dc.date.accessioned2008-06-12T06:33:25Z-
dc.date.available2008-06-12T06:33:25Z-
dc.date.issued1995en_HK
dc.identifier.citationJournal Of Clinical Microbiology, 1995, v. 33 n. 10, p. 2530-2534en_HK
dc.identifier.issn0095-1137en_HK
dc.identifier.urihttp://hdl.handle.net/10722/49054-
dc.description.abstractA nested PCR assay for the detection of human cytomegalovirus (CMV) DNA was evaluated by weekly monitoring of blood samples taken from 101 bone marrow transplant (BMT) recipients. When peripheral blood leukocytes were used as the source of CMV DNA, even a modified assay with stringent temperature-cycling conditions was as sensitive as the standard assay. The sensitivity, specificity, and positive predictive value of two consecutively positive leukocytic PCR results with this modified assay in predicting CMV disease of 101 patients submitting 1,441 peripheral blood leukocyte samples were found to be 92.1, 63.5, and 60.3%, respectively. The positive predictive value of patients' seropositivity for CMV was 40%, while that of viremia was 72%. However, viremia followed CMV disease by a median of 1.5 days, while the first leukocytic positive PCR assay preceded disease by a median of 14 days. By use of the criteria of two consecutively positive PCR results instead of recipient CMV seropositivity for starting preemptive ganciclovir treatment, 38 of the 43 recipients with isolated single positive or negative assays (groups I and II) would be spared unnecessary ganciclovir treatment. Moreover, two other findings support the use of antiviral prophylaxis before engraftment in high-risk cases and subsequent preemptive treatment of patients with two consecutively positive PER assays. First, for 7.9% of 76 patients with positive assays (groups II and III), the first positive PCR assay occurred before engraftment, which implied the presence of viral DNA in the blood (DNAemia) soon after transplantation. Second, isolated single positive assays which were clustered around the second to sixth weeks after transplantation were found for 18 patients (group II) and could represent abortive episodes of CMV infection.en_HK
dc.format.extent418 bytes-
dc.format.mimetypetext/html-
dc.languageengen_HK
dc.publisherAmerican Society for Microbiology.en_HK
dc.relation.ispartofJournal of Clinical Microbiologyen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.rightsJournal of Clinical Microbiology. Copyright © American Society for Microbiology.en_HK
dc.rightsCopyright © American Society for Microbiology, Journal of Clinical Microbiology, 1995, v. 33 n. 10, p. 2530-2534en_HK
dc.subject.meshBone Marrow Transplantation - adverse effectsen_HK
dc.subject.meshCytomegalovirus Infections - blood - diagnosis - epidemiologyen_HK
dc.subject.meshDNA, Viral - genetics - isolation & purificationen_HK
dc.subject.meshLeukocytes - virologyen_HK
dc.subject.meshPolymerase Chain Reaction - methodsen_HK
dc.titleMonitoring of leukocyte cytomegalovirus DNA in bone marrow transplant recipients by nested PCRen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0095-1137&volume=33&issue=10&spage=2530&epage=2534&date=1995&atitle=Monitoring+of+leukocyte+cytomegalovirus+DNA+in+bone+marrow+transplant+recipients+by+nested+PCRen_HK
dc.identifier.emailYuen, KY:kyyuen@hkucc.hku.hken_HK
dc.identifier.emailWong, SSY:samsonsy@hkucc.hku.hken_HK
dc.identifier.emailLau, YL:lauylung@hkucc.hku.hken_HK
dc.identifier.emailLiang, R:rliang@hku.hken_HK
dc.identifier.authorityYuen, KY=rp00366en_HK
dc.identifier.authorityWong, SSY=rp00395en_HK
dc.identifier.authorityLau, YL=rp00361en_HK
dc.identifier.authorityLiang, R=rp00345en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.pmid8567878-
dc.identifier.pmcidPMC228523-
dc.identifier.scopuseid_2-s2.0-0029147070en_HK
dc.identifier.hkuros14680-
dc.identifier.volume33en_HK
dc.identifier.issue10en_HK
dc.identifier.spage2530en_HK
dc.identifier.epage2534en_HK
dc.identifier.isiWOS:A1995RV56500002-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridYuen, KY=36078079100en_HK
dc.identifier.scopusauthoridLo, SKF=7401542391en_HK
dc.identifier.scopusauthoridChiu, EKW=24827833600en_HK
dc.identifier.scopusauthoridWong, SSY=13310021400en_HK
dc.identifier.scopusauthoridLau, YL=7201403380en_HK
dc.identifier.scopusauthoridLiang, R=26643224900en_HK
dc.identifier.scopusauthoridChan, TK=37076590700en_HK
dc.identifier.scopusauthoridNg, MH=7202076421en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats